5 things to look for Thursday in Lilly’s earnings
Executives at Eli Lilly and Co. are telling investors the worst is behind the company and only good things await. But the drugmaker still has a few things to prove.
Eli Lilly & Co.
Articles
Lilly CEO: Drugmakers getting bum rap
Eli Lilly and Co. CEO John Lechleiter told Wall Street analysts recently that, while there have been “individual huge drug price increases,” the overall cost of drugs is rising very slowly and remains a small part of overall U.S. health care spending.
Eskenazi launches $50M effort to take brain care around the world
The safety-net hospital system in Indianapolis will create the Center for Brain Care Innovation and try to use telemedicine and a digital avatar to reach as many as 150,000 Hoosiers and 10 million patients outside Indiana by 2030.
Go figure: As patients’ anger over costs spikes, health care prices barely budge
Patients’ anger over high deductibles and high drug prices is spurring presidential candidates to respond—even as the actual prices of health care services are growing slower than at any time since 1990.
Analyst: Lilly’s Jardiance diabetes pill could be a $6 billion-a-year blockbuster
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.
Surprising heart study could bring Lilly $1B annually
Eli Lilly and Co. didn’t win approval for a new drug last week. But its latest study of an existing diabetes drug could create a blockbuster in its own right—adding as much as $1 billion a year to the coffers of the Indianapolis-based drugmaker.
Indiana health care investments simmer while national market sizzles
Hoosier entrepreneurs in health care and life sciences attracted more than $31 million from investors during the first half of the year. But too few Indiana companies have developed their technology enough to attract venture capitalists or tap stock markets.
Lilly expands R&D outside Indy—again
State and city leaders spend millions each year to entice companies to move here and add jobs here. But for the second time in three months, Eli Lilly and Co. has shown that the biggest attraction to a company is talented workers.
Lilly, Anthem show high risk, high reward strategy can pay off
The CEOs of Eli Lilly and Anthem are being rewarded by investors for taking high-risk approaches to develop breakthrough drugs, make major acquisitions.
Lilly faces moment of truth this week
The Indianapolis-based drugmaker on Wednesday will release new data from patients taking its Alzheimer’s drug that could show whether the drug has slowed the progression of their disease. That will show investors whether the 45 percent rise in Lilly’s stock price over the past year is justified.
Indiana’s medical research ‘trade deficit’
Indiana's life sciences companies are spending four times more on medical research than the state's hospitals, doctors and univerities are receiving from such companies for research projects. That means Indiana is missing out on more than $80 million a year.
Fate of Eli Lilly’s potential $2B blockbuster insulin hangs on side effects
Lilly’s basal insulin peglispro proved more effective than the $7 billion blockbuster Lantus at controlling diabetics’ blood sugar, but it also had greater effect on patients’ livers and hearts. Analysts are unsure of its future.
How ‘losing’ the headquarters of two promising drug firms could help Indiana
The fact that Assembly Biosciences Inc. and AgeneBio now list New York and Baltimore, respectively, as their headquarters cities doesn’t hurt Indiana and could help the state, says David Johnson, CEO of BioCrossroads.
Hoosier docs enjoy more than $40M a year from drug, device firms
New research shows patients lose trust and confidence in doctors that take money for travel, but like it when their doctors are paid as consultants during the development of new products.
Killing obesity without coercion
Top-down culture change only works in North Korea, says the head of a group of local CEOs that is working broadly and subtly, not tyrannically, to improve Indy’s culture of eating and exercising.
CEO Roundup: We’re not your father’s health care company anymore
The CEOs of Anthem, Lilly, Zimmer and Hill-Rom tried to woo investors at the J.P. Morgan Healthcare conference by stressing how they’re broadening business beyond plain-old insurance, pharmaceuticals, implants and hospital beds.
Obamacare’s effects on Lilly: Modest pain, no gain
Since Obamcare was expected to boost insurance coverage nationally by 32 million people, drugmakers like Eli Lilly and Co. stood to benefit. But it’s not working out that way. At least not for Lilly.
Top 4 questions for Hoosier health care after GOP takes control of Congress
On Obamacare, the new Republican-controlled Congress should “leave the façade of the building and then demolish the inside of it,” according to one GOP leader. If Republicans take that approach, here are four things that could change in the next two years.
Lechleiter: It’s morning at Eli Lilly
Lilly CEO John Lechleiter kicked off the company’s quarterly conference call with investors and analysts by declaring an end to the “unprecedented challenge” that Lilly lived through the past four years.
More patients help drug firms pass ‘valley of death’
In spite of the beaucoup bucks in the pharma sector, patients, along with their families and committed advocates, are turning out to be better sources of funding for early stage companies because they tolerate risk better than drug companies and investors.